Author of

• 14306

  +

  P2.01 - Poster Session/ Treatment of Advanced Diseases – NSCLC (ID 207)

  • Event: WCLC 2015
  • Type: Poster
  • Track: Treatment of Advanced Diseases - NSCLC
  • Presentations: 1
  • Moderators:
  • Coordinates: 9/08/2015, 09:30 - 17:00, Exhibit Hall (Hall B+C)

  • 14328

    +

    P2.01-022 - BMI as Factor Predicting the Efficacy of Gefitinib in NSCLC with EGFR Mutation (ID 117)

    09:30 - 09:30  |  Author(s): W. Ziping
    • Abstract
    • Slides

    Background:
    Many randomized clinical trials have demonstrated that epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) are advantageous over standard chemotherapy either as front-line treatment or as further management of patients with EGFR mutation-positive non-small-cell lung cancer (NSCLC). But which subgroup of patients with EGFR mutation-positive advanced NSCLC could benefit more from EGFR-TKIs needs to be further explored. In the present study, we attempted to explore predictive factors in such cohorts of patients who received gefitinib by classification and regression tree (CART) analysis.
    
    Methods:
    Included in this study were 95 patients with EGFR mutation-positive advanced NSCLC who received gefitinib treatment at the Cancer Institute (Hospital) of the Chinese Academy of Medical Sciences between February 2010 and October 2013. Multivariate analysis of progression-free survival (PFS) was performed using recursive partitioning referred to as CART analysis to assess the effect of specific variables on PFS in subgroups of patients with similar clinical features.
    
    Results:
    The median PFS in patients with EGFR mutation-positive advanced NSCLC who received gefitinib treatment was 13.3 months (95% CI 9.4-17.2). CART analysis showed an initial split on body mass index (BMI), based on which three terminal subgroups were formed. The median PFS in the three subsets ranged from 8.2 months to 15.2 months, in which the subgroup with a BMI less than or equal to 20.768Kg/m2 had the longest PFS (15.2 months). In addition, PFS in EGFR exon 19 mutation group was better than that in other mutation site group (10.3 vs. 8.2 months).
    
    Conclusion:
    BMI and exon 19 mutation are predictors of PFS in patients with EGFR mutation-positive advanced NSCLC who received gefitinib treatment. Both active EGFR mutation and patient’s own factors could be used to predict the therapeutic efficacy of EGFR-TKIs. Figure 1Figure 2
    
    
    
    
    
    

    Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.